Batsheva Kerem

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

SPL84 and trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variants.

SPL84 and trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variants.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: March 14, 2026

Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis.

Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 27, 2025

Hypertranscription caused by p53 deficiency triggers nucleotide insufficiency that induces replication stress and genomic instability.

Hypertranscription caused by p53 deficiency triggers nucleotide insufficiency that induces replication stress and genomic instability.

Journal: Molecular cell
Published: July 14, 2025

The response of rare CFTR mutations to specific modulator combinations.

The response of rare CFTR mutations to specific modulator combinations.

Journal: ERJ open research
Published: December 08, 2024

Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients.

Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients.

Journal: Nucleic acid therapeutics
Published: August 29, 2023

Insights into common fragile site instability: DNA replication challenges at DNA repeat sequences.

Insights into common fragile site instability: DNA replication challenges at DNA repeat sequences.

Journal: Emerging topics in life sciences
Published: August 02, 2023

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: January 06, 2023

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: September 12, 2022

Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability.

Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability.

Journal: Cell reports
Published: March 05, 2022

Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.

Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 23, 2021

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 28, 2021

3D genome organization contributes to genome instability at fragile sites.

3D genome organization contributes to genome instability at fragile sites.

Journal: Nature communications
Published: November 28, 2019
Showing 1-12 of 33

Last Updated: 09/26/2026